Intellia Therapeutics (NTLA) Receivables - Net (2016 - 2025)
Historic Receivables - Net for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to $11.0 million.
- Intellia Therapeutics' Receivables - Net rose 2480.23% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year increase of 2480.23%. This contributed to the annual value of $8.5 million for FY2024, which is 7663.76% down from last year.
- Per Intellia Therapeutics' latest filing, its Receivables - Net stood at $11.0 million for Q3 2025, which was up 2480.23% from $11.4 million recorded in Q2 2025.
- In the past 5 years, Intellia Therapeutics' Receivables - Net registered a high of $36.5 million during Q4 2023, and its lowest value of $953000.0 during Q1 2021.
- Moreover, its 5-year median value for Receivables - Net was $5.1 million (2023), whereas its average is $9.0 million.
- Its Receivables - Net has fluctuated over the past 5 years, first tumbled by 9287.1% in 2021, then skyrocketed by 86751.59% in 2023.
- Quarter analysis of 5 years shows Intellia Therapeutics' Receivables - Net stood at $2.0 million in 2021, then soared by 85.52% to $3.8 million in 2022, then soared by 867.52% to $36.5 million in 2023, then tumbled by 76.64% to $8.5 million in 2024, then increased by 29.74% to $11.0 million in 2025.
- Its Receivables - Net stands at $11.0 million for Q3 2025, versus $11.4 million for Q2 2025 and $10.5 million for Q1 2025.